natgillin/translations-raw huggingface dataset:
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1,800 mg/kg/day.
Ispitivanje peri- i postnatalnog razvoja provedeno je u štakora dozama levetiracetama od 70, 350 i 1800 mg/kg/dan.
To measure the dosing quantity, use one hand to hold the dosing body and the other hand to pull up the plunger until you reach the graduation mark corresponding to the quantity in milliliters (ml) prescribed by your doctor (Figure 1).
Kako biste odmjerili potrebnu dozu, s jednom rukom primite tijelo graduirane štrcaljke a s drugom izvucite njen klip do oznake koja odgovara količini u mililitrima (ml)
Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified.
Levetiracetam u dozi od 2000 mg na dan nije utjecao na farmakokinetiku digoksina i varfarina; protrombinsko vrijeme ostalo je nepromijenjeno.
• depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
• depresija, netrpeljivost ili agresivnost, tjeskoba, nesanica, nervoza ili razdražljivost;
Creatinine clearance (ml/min/1.73m2)
Klirens kreatinina (ml/min/1,73 m2)
The primary measure of effectiveness was the responder rate (percent of patients with ≥ 50% reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG.
Primarna mjera učinkovitosti bila je stopa bolesnika s odgovorom (postotak bolesnika u kojih je dnevna prosječna učestalost napadaja smanjena za ≥ 50 % u odnosu na početno stanje) određena središnjim pregledavanjem 48-satnog video EEG-a od strane ocjenjivača koji nije znao tko je dobivao placebo, a tko lijek.
After oral administration the bitter taste of levetiracetam may be experienced.
Nakon peroralne primjene može se očekivati gorak okus levetiracetama.
• Levetiracetam Actavis Group is used as a chronic treatment.
• Levetiracetam Actavis Group se koristi za dugotrajno liječenje.
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
Djelotvornost levetiracetama dokazana je u dvostruko slijepom i placebom kontroliranom ispitivanju u trajanju od 24 tjedna, koje je uključivalo odrasle, adolescente i ograničeni broj djece s idiopatskom generaliziranom epilepsijom s primarno generaliziranim toničko-kloničkim (PGTK) napadajima kod različitih sindroma (juvenilna mioklonična epilepsija, epilepsija s apsansima dječje i juvenilne dobi ili epilepsija s grand mal napadajima kod buđenja).
The pharmacokinetic profile is linear with low intra- and inter-subject variability.
Farmakokinetički profil je linearan, a varijabilnost je niska i među različitim bolesnicima i za istog bolesnika.
Clear, faint yellowish-brown solution.
Bistra, blijedo žućkasto-smeđa otopina.
Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase.
Levetiracetam malo ili umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima Uslijed mogućih razlika u osjetljivosti među pojedincima, u nekih bolesnika može se javiti somnolencija ili drugi simptomi vezani za središnji živčani sustav, osobito na početku liječenja ili nakon povećanja doze.
In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).
Bolesnici su u tom ispitivanju dobivali konstantnu dozu od 60 mg/kg/dan (doziranje dva puta na dan).
Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam.
Probenecid (500 mg četiri puta na dan), inhibitor bubrežne tubularne sekrecije, inhibira bubrežni klirens glavnog metabolita levetiracetama, ali ne i samog levetiracetama.
The oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Oralna otopina najprikladniji je farmaceutski oblik za primjenu kod dojenčadi i djece mlađe od 6 godina.
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day.
Četiri ispitivanja embrio-fetalnog razvoja provedena su u kunića s dozama od 200, 600, 800, 1200 i 1800 mg/kg/dan.
A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study.
20 mg/kg/dan titrirana je do 40 mg/kg/dan u dojenčadi u dobi od jednog do manje od 6 mjeseci, a doza od 25 mg/kg/dan titrirana je do 50 mg/kg/dan u dojenčadi i djece u dobi od 6 mjeseci do manje od 4
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, noninferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy.
Djelotvornost levetiracetama za samostalno liječenje dokazana je kod paralelnih grupa u dvostruko slijepoj usporedbi neinferiornosti s karbamazepinom s kontroliranim otpuštanjem (CR, engl. controlled release) na 576 bolesnika u dobi od 16 godina ili starijih s novo- ili nedavno dijagnosticiranom epilepsijom.
Drug reaction with eosinophilia and systemic symptoms (DRESS), Hypersensitivity (including angioedema and anaphylaxis)
Reakcija na lijek s eozinofilijom i sistemskim simptomima (DRESS), preosjetljivost
43.6% of the levetiracetam treated patients and 19.6% of the patients on placebo were considered as responders.
U 44,6 % bolesnika liječenih levetiracetamom i 19,6 % bolesnika koji su dobivali placebo, zapaženo je
Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment.
Opisani su rijetki slučajevi smanjenog broja krvnih stanica (neutropenija, agranulocitoza, leukopenija, trombocitopenija i pancitopenija) koji su povezani s primjenom levetiracetama, obično na početku liječenja.
Each ml contains 100 mg of levetiracetam.
Jedan ml sadrži 100 mg levetiracetama.
• cough;
• kašalj;
Steady-state is achieved after two days of a twice daily administration schedule.
Stanje dinamičke ravnoteže postiže se nakon dva dana doziranja dva puta na dan.
You should not stop your treatment without discussing this with your doctor.A risk of birth defects for your unborn child cannot be completely excluded.
Rizik od prirođenih mana za Vaše nerođeno dijete ne može se u potpunosti isključiti.
Dose in adults and adolescents from 16 years of age:
Doza za odrasle i adolescente od 16. godine života:
Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours.
Nakon primjene jedne oralne doze (20 mg/kg) u djece s epilepsijom (6 do 12 godina) poluvijek levetiracetama bilo je 6,0 sati.
Each ml contains 1.50 mg of methyl parahydroxybenzoate (E218), 0.15 mg of propyl parahydroxybenzoate (E216), 290 mg of maltitol liquid (E965), 3,26 mg propylene glycol (E 1520) and 0.25 mg of sodium.
Jedan ml sadrži 1,50 mg metilparahidroksibenzoata (E218), 0,15 mg propilparahidroksibenzoata (E216), 290 mg tekućeg maltitola (E965), 3,26 mg propilenglikola (E1520) i 0,25 mg natrija.
Acute kidney injury
Akutno oštećenje bubrega
Take the syringe and pull back the plunger a little way (Figure 2).
Uzmite štrcaljku i malo izvucite klip (slika 2).
Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function:
Prilagođavanje doze za odrasle bolesnike i adolescente teške više od 50 kg s oštećenom bubrežnom funkcijom
Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing.
Nakon primjene jedne doze (20 mg/kg) 100 mg/ml oralne otopine u djece s epilepsijom (1 mjesec do 4 godine) levetiracetam se brzo apsorbira te je vršna koncentracija u plazmi postignuta približno 1 sat nakon uzimanja lijeka.
The possible side effects of an overdose of Levetiracetam Actavis Group are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Moguće nuspojave predoziranja lijekom Levetiracetam Actavis Group su pospanost, uznemirenost, agresija, smanjena pozornost, smetnje disanja i koma.
Contact your doctor if you took more Levetiracetam Actavis Group than you should.
Obavijestite liječnika ako ste uzeli veću količinu lijeka Levetiracetam Actavis Group nego što ste trebali.
Levetiracetam Actavis Group contains methyl parahydroxybenzoate, propyl parahydroxybenzoate, maltitol, propylene glycol and sodium.
Levetiracetam Actavis Group sadrži metilparahidroksibenzoat, propilparahidroksibenzoat, maltitol, propilenglikol i natrij.
• muscle weakness, myalgia (muscle pain);
• slabost mišića, mijalgija (bol u mišićima);
• vertigo (sensation of rotation);
• vrtoglavica (osjećaj vrtnje);
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants aged 1 month to less than 6 months.
Kako bi se osiguralo točno doziranje to pakiranje treba propisivati dojenčadi u dobi od 1 mjeseca do manje od 6 mjeseci.
Levetiracetam Actavis Group oral solution contains propylene glycol (E1520).
Levetiracetam Actavis Group oralna otopina sadrži propilenglikol (E1520).
This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.
Iz toga proizlazi da interakcija levetiracetama i sinaptičkog vezikularnog proteina 2A vjerojatno pridonosi antiepileptičkom mehanizmu djelovanja lijeka.
Other medicines and Levetiracetam Actavis Group
Drugi lijekovi i Levetiracetam Actavis Group
Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily.
Ovisno o kliničkom odgovoru i podnošljivosti lijeka, doza se može povećati do 30 mg/kg dva puta na dan.
Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.
Primjena levetiracetama zajedno s digoksinom, oralnim kontraceptivima i varfarinom nije utjecala na farmakokinetiku levetiracetama.
Instruction for use for 1 ml and 3 ml syringes with an adaptor
Upute za uporabu za štrcaljke od 1 ml i 3 ml s nastavkom
No tissue distribution data are available in humans.
Nema podataka o raspodjeli ovog lijeka u tkivima kod ljudi.
Levetiracetam Actavis Group oral solution also contains maltitol.
Levetiracetam Actavis Group oralna otopina također sadrži maltitol.
Pancytopenia, neutropenia, agranulocytosis
Pancitopenija, neutropenija, agranulocitoza
72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week.
U 72,2 % bolesnika liječenih levetiracetamom i 45,2 % bolesnika koji su dobivali placebo primijećeno je 50 %-tno ili više smanjenje učestalosti PGTK napadaja tjedno.
Turn the bottle the right way up and remove the syringe (Figure 8).
Vratite bocu u uspravan položaj i uklonite štrcaljku (slika 8).
Levetiracetam Actavis Group is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Levetiracetam Actavis Group je indiciran kao monoterapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih i adolescenata od 16. godine života s novodijagnosticiranom epilepsijom.
Levetiracetam Actavis Group oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).
Levetiracetam Actavis Group oralna otopina sadrži metilparahidroksibenzoat (E218) i propilparahidroksibenzoat (E216) koji mogu izazvati alergijske reakcije (koje mogu biti i odgođene).
If you take more Levetiracetam Actavis Group than you should
Ako uzmete više lijeka Levetiracetam Actavis Group nego što ste trebali
Levetiracetam Actavis Group is not indicated in children and adolescents below 16 years on its own (monotherapy).
U djece i adolescenata mlađih od 16 godina Levetiracetam Actavis Group se ne primjenjuje samostalno (monoterapija).
Infants should start the treatment with Levetiracetam Actavis Group 100 mg/ml oral solution.
Dojenčad treba započeti liječenje sa Levetiracetam Actavis Group 100 mg/ml oralnom otopinom.
Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks.
Promjena doze ne smije premašiti povećanja ili smanjenja za 10 mg/kg dva puta na dan svaka dva tjedna.
From 50 kg (2)
Iznad 50 kg (2)
500 to 1,000 mg once daily (2)
500 do 1000 mg jedanput na dan (2)
Levetiracetam Actavis Group 100 mg/ml oral solution contains 3,26 mg propylene glycol (E1520) in each ml.
Levetiracetam Actavis Group 100 mg/ml oralna otopina sadrži 3,26 mg propilenglikola (E1520) u jednom ml.
You should not drive or use machines until it is established that your ability to perform such activities is not affected.
Ne smijete voziti ili se koristiti strojevima dok se ne utvrdi da uzimanje lijeka Levetiracetam Actavis Group ne utječe na Vaše sposobnosti za to.
Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability
Depresija, netrpeljivost/ agresivnost, anksioznost, nesanica, nervoza/razdražljivost
Specialist advice should be given to women who are of childbearing potential.
Žene reproduktivne dobi treba savjetovati specijalist.
Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily.
Ovisno o kliničkom odgovoru i podnošljivosti lijeka, dnevna doza može se povećati do 1500 mg dva puta na dan.
Dose and frequency (1) Infants 1 to less than 6 months
Doza i učestalost primjene (1) Dojenčad od 1 mjeseca do manje od 6 mjeseci
Dose changes should not exceed increases or decreases of 7 mg/kg twice daily every two weeks.
Promjena doze ne smije premašiti povećanja ili smanjenja za 7 mg/kg dva puta na dan svaka dva tjedna.
The other ingredients are: sodium citrate, citric acid monohydrate, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), ammonium glycyrrhizate, glycerin, glycerol (E422), maltitol liquid (E965), acesulfame potassium (E950), grape flavour (contains propylene glycol), purified water.
Drugi sastojci su: natrijev citrat, citratna kiselina hidrat, metilparahidroksibenzoat (E218), propilparahidroksibenzoat (E216), amonijev glicirizat, glicerin, glicerol (E422), tekući maltitol (E965), acesulfamkalij (E950), aroma grožđa (sadrži propilenglikol), pročišćena voda.
In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks.
U pedijatrijskih bolesnika (4 do 16 godina života) djelotvornost levetiracetama dokazana je u dvostruko slijepom i placebom kontroliranom ispitivanju koje je trajalo 14 dana i uključivalo 198 bolesnika.
For children aged 1 month to less than 6 months.
Za djecu u dobi od 1 mjeseca do manje od 6 mjeseci.
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1,200 and 3,600 mg/kg/day.
Provedena su dva ispitivanja embrio-fetalnog razvoja (engl. embryo-fetal development, EFD) u štakora s dozama od 400, 1200 i 3600 mg/kg/dan.
Balkanpharma-Troyan AD 1 Krayrechna Str, Troyan 5600
Balkanpharma-Troyan AD 1 Krayrechna Str,
The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.
Hrana ne utječe na opseg apsorpcije levetiracetama, ali blago smanjuje brzinu apsorpcije.
The active substance is called levetiracetam.
Djelatna tvar je levetiracetam.
Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy.
Levetiracetam i srodni analozi s različitim se afinitetom vežu za sinaptički vezikularni protein 2A, a to je, u mišjem modelu audiogene epilepsije, povezano s potencijalom zaštite od napada.
In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam.
U osoba s blagim i umjerenim oštećenjem jetre klirens levetiracetama nije bitno promijenjen.
The maximum dose is 1,500 mg twice daily.
Maksimalna je doza 1500 mg dva puta na dan.
Open the bottle and push the syringe adaptor firmly into the bottle neck (Figure 1).
Otvorite bocu i dobro utisnite nastavak za štrcaljku na vrat boce (slika 1).
Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) Levetiracetam Actavis Group 100 mg/ml oral solution contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).
Metilparahidroksibenzoat (E218) i propilparahidroksibenzoat (E216) Levetiracetam Actavis Group 100 mg/ml oralna otopina sadrži metilparahidroksibenzoat (E218) i propilparahidroksibenzoat (E216) koji mogu izazvati alergijske reakcije (koje mogu biti i odgođene).
In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days.
U pedijatrijskih bolesnika (1 mjesec do manje od 4 godine života) djelotvornost levetiracetama dokazana je dvostruko slijepim i placebom kontroliranim ispitivanjem u 116 bolesnika koji su lijek dobivali 5 dana.
Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes.
Djelotvornost levetiracetama dokazana je u dvostruko slijepom i placebom kontroliranom 16-tjednom ispitivanju u koje su bili uključeni bolesnici od 12 godina života i stariji s idiopatskom generaliziranom epilepsijom s miokloničkim napadajima kod različitih sindroma.
Wash the syringe with water after use and close the bottle with the plastic screw cap (Figure 10).
Nakon uporabe štrcaljku isperite s vodom a bocu zatvorite plastičnim zatvaračem s navojem (slika 10).
Levetiracetam is not extensively metabolised in humans.
Levetiracetam se kod ljudi ne metabolizira značajno.
Management of overdose
Postupak kod predoziranja
Should your doctor decide to stop your Levetiracetam Actavis Group treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Actavis Group.
Ako prekidate liječenje lijekom Levetiracetam Actavis Group, , prekid mora biti postupan kako bi se izbjeglo pojačanje napadaja.Ako Vaš liječnik odluči prekinuti liječenje lijekom Levetiracetam Actavis Group, uputit će Vas kako postupno prekinuti liječenje lijekom Levetiracetam Actavis Group.
As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.
Kako ni u odraslih, tako ni u pedijatrijskih bolesnika koji su dobivali do 60 mg/kg/dan levetiracetama nema dokaza o klinički značajnim interakcijama s lijekovima.
Adjustment of the dose is recommended in elderly patients with compromised renal function (see “Renal impairment” below).
U starijih bolesnika sa smanjenom bubrežnom funkcijom preporučuje se prilagođavanje doze (vidjeti “Oštećenje bubrega” ispod).
Wash the syringe with water after use and close the bottle with the plastic screw cap (Figure 4).
Nakon uporabe štrcaljku isperite s vodom a bocu zatvorite plastičnim zatvaračem s navojem (slika 4).
However, data suggested a 20 % higher levetiracetam clearance in children taking enzymeinducing antiepileptic medicinal products.
Međutim, podaci su pokazali da antiepileptici koji induciraju enzimsku aktivnost kod djece povisuju klirens levetiracetama za 20%.
• suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger,
• pokušaj samoubojstva i suicidalne misli, mentalni poremećaj, poremećaj ponašanja,
Dosing adjustment for infants, children and adolescent patients weighing less than 50 kg with impaired renal function:
Prilagođavanje doze kod dojenčadi, djece i adolescenata s manje od 50 kg tjelesne težine s oštećenom bubrežnom funkcijom Skupina
The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
Kod monoterapije u djece i adolescenata mlađih od 16 godina sigurnost i djelotvornost levetiracetama nije dokazana.
28 mg (0.3 ml) twice daily 84 mg (0.85 ml) twice daily
28 mg (0,3 ml) dva puta na dan 84 mg (0,85 ml) dva puta na dan
Rare: may affect up to 1 in 1,000 people
Rijetko: mogu se javiti u manje od 1 na 1000 osoba
Levetiracetam has been given to you by your doctor to reduce the number of fits.
Vaš liječnik Vam je propisao levetiracetam kako bi se smanjio broj napadaja.
35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months.
U placebom kontroliranim kliničkim ispitivanjima lijeku je bilo izloženo 35 dojenčadi mlađe od 1 godine s parcijalnim napadajima, a samo je njih 13 bilo u dobi ˂ 6 mjeseci.
General dose: Levetiracetam Actavis Group is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml (500 mg) and 15 ml (1,500 mg).
Uobičajena doza: Levetiracetam Actavis Group se uzima dva puta na dan, u dvije jednake doze, pri čemu svaka pojedinačna doza iznosi između 5 ml (500 mg) i 15 ml (1500 mg).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6- 17 the MRHD on a mg/m2 basis).
Neonatalna i juvenilna ispitivanja na štakorima i psima pokazala su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
General dose: Levetiracetam Actavis Group is taken twice daily, in two equally divided doses, each individual dose being measured between 0.07 ml (7 mg) and 0.21 ml (21 mg), per kg bodyweight of the infant.
Uobičajena doza: Levetiracetam Actavis Group se uzima dva puta na dan, u dvije jednake doze, pri čemu svaka pojedinačna doza iznosi između 0,07 ml (7 mg) i 0,21 ml (21 mg) po kilogramu tjelesne težine dojenčeta.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores.
Studije in vitro pokazuju da levetiracetam utječe na razinu Ca2+ u neuronima na način da djelomično inhibira
• signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements.
izrazitu pospanost, amneziju (gubitak pamćenja), slabljenje pamćenja (zaboravljivost), abnormalno ponašanje ili druge neurološke znakove uključujući nevoljne ili nekontrolirane pokrete.
Levetiracetam Actavis Group treatment for as long as your doctor has told you.
Trebate nastaviti liječenje lijekom Levetiracetam Actavis Group onoliko dugo koliko je liječnik odredio.
Dose recommendations for infants aged from 1 month to less than 6 months:
Preporučene doze za dojenčad u dobi od 1 mjeseca do manje od 6 mjeseci: